Author(s):
Shree Pavithra D, Sowmiyaa P, Jananipriya M K, Venkateswaramurthy N
Email(s):
nvmurthi@gmail.com
DOI:
10.52711/2321-5836.2026.00030 
Address:
Shree Pavithra D, Sowmiyaa P, Jananipriya M K, Venkateswaramurthy N*
Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Kumarapalayam - 638183, Namakkal District, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2026
ABSTRACT:
Liquid biopsy has emerged as a transformative approach in oncology, offering minimally invasive means for cancer detection, molecular characterization, and longitudinal disease monitoring. Among the diverse biosources available for liquid biopsy, tumor-educated platelets (TEPs) have garnered substantial interest as a rich and dynamic source of RNA-based biomarkers. Unlike circulating tumor DNA, which may present with low mutant allele fractions in early-stage disease, platelets offer abundant and relatively stable RNA that can be isolated from routine blood draws. Platelets, though anucleate, harbor megakaryocyte-derived messenger RNA and possess the capacity for RNA processing, enabling them to generate diverse transcriptomic repertoires. Importantly, platelets can sequester tumor-derived RNA from the circulation and through contact with tumor cells, producing disease-specific RNA signatures that can be captured through RNA sequencing and analysed using machine learning algorithms. Pan-cancer studies have demonstrated that TEP profiles can distinguish cancer patients from healthy controls with high accuracy, identify the primary site of tumor origin, and detect actionable molecular alterations. Disease-specific investigations have further validated TEP-based diagnostics across multiple solid tumor types, including non-small cell lung cancer, glioblastoma, colorectal cancer, ovarian cancer, pancreatic cancer, and sarcoma. Beyond diagnosis, TEP RNA signatures exhibit dynamic changes during treatment, supporting their application in monitoring therapeutic response and detecting disease progression. Nevertheless, critical challenges remain, including protocol sensitivity, pre-analytical confounding, and the need for rigorous prospective validation. This narrative review comprehensively examines the biological foundations of platelet tumor-RNA sequestration, synthesizes evidence on diagnostic and monitoring performance across cancer types, discusses technical platforms and computational methodologies, addresses limitations and negative findings, compares TEPs with other liquid biopsy modalities, and delineates future research priorities necessary to translate this promising approach into clinical practice.
Cite this article:
Shree Pavithra D, Sowmiyaa P, Jananipriya M K, Venkateswaramurthy N. Tumor-Educated Platelet RNA Profiling for Cancer Detection and Treatment Monitoring: A Comprehensive Narrative Review. Research Journal of Pharmacology and Pharmacodynamics.2026;18(3):219-8. doi: 10.52711/2321-5836.2026.00030
Cite(Electronic):
Shree Pavithra D, Sowmiyaa P, Jananipriya M K, Venkateswaramurthy N. Tumor-Educated Platelet RNA Profiling for Cancer Detection and Treatment Monitoring: A Comprehensive Narrative Review. Research Journal of Pharmacology and Pharmacodynamics.2026;18(3):219-8. doi: 10.52711/2321-5836.2026.00030 Available on: https://www.rjppd.org/AbstractView.aspx?PID=2026-18-3-1
REFERENCES:
1. Nilsson RJA, Balaj L, Hulleman E, van Rijn S, Pegtel DM, Walraven M, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood. 2011; 118(13): 3680-3683. doi:10.1182/blood-2011-03-344408
2. Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, et al. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell. 2015; 28(5): 666-676. doi: 10.1016/j.ccell.2015.09.018
3. In 't Veld SGJG, Arkani M, Post E, Antunes-Ferreira M, D'Ambrosi S, Vessies D, et al. Detection and localization of early- and late-stage cancers using platelet RNA. Cancer Cell. 2022; 40(9): 999-1009.e6. doi: 10.1016/j.ccell.2022.08.006
4. Best MG, Sol N, In't Veld SGJG, Vancura A, Muller M, Niemeijer AN, et al. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell. 2017; 32(2): 238-252.e9. doi: 10.1016/j.ccell.2017.07.004
5. Sol N, In 't Veld SGJG, Vancura A, Tjerkstra M, Leurs C, Rustenburg F, et al. Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma. Cell Rep Med. 2020; 1(7): 100101. doi: 10.1016/j.xcrm.2020.100101
6. Xu L, Li X, Li X, Wang X, Ma Q, She D, et al. RNA profiling of blood platelets noninvasively differentiates colorectal cancer from healthy donors and noncancerous intestinal diseases: a retrospective cohort study. Genome Med. 2022; 14(1): 26. doi:10.1186/s13073-022-01033-x
7. Gao Y, Liu C, Li H, Xiong X, Li G, In't Veld SGJG, et al. Platelet RNA enables accurate detection of ovarian cancer: an intercontinental, biomarker identification study. Protein Cell. 2023; 14(6): 579-590. doi:10.1093/procel/pwac056
8. Ahn EH, Kim SH, Park SW, Kim SH, Kim HA, Lee HJ, et al. Innovative qPCR Algorithm Using Platelet-Derived RNA for High-Specificity and Cost-Effective Ovarian Cancer Detection. Cancers (Basel). 2025; 17(7): 1251. doi:10.3390/cancers17071251
9. Ji W, Xiong Y, Yang W, Shao Z, Guo X, Jin G, et al. Transcriptomic profiling of blood platelets identifies a diagnostic signature for pancreatic cancer. Br J Cancer. 2025; 132(10): 937-946. doi:10.1038/s41416-025-02980-z
10. Heinhuis KM, In't Veld SGJG, Dwarshuis G, van den Broek D, Sol N, Best MG, et al. RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics. Cancers (Basel). 2020; 12(6): 1372. doi:10.3390/cancers12061372
11. Zhang Q, Bi Z, Song X, Zhang Y, Wang S, Xie L, Song X. Tumor-educated platelet SNORA58, SNORA68 and SNORD93 as novel diagnostic biomarkers for esophageal cancer. Future Oncol. 2023; 19(9): 651-661. doi:10.2217/fon-2023-0129
12. Gill JS, Bansal B, Poojary R, Singh H, Huang F, Weis J, et al. Immunological Signatures for Early Detection of Human Head and Neck Squamous Cell Carcinoma through RNA Transcriptome Analysis of Blood Platelets. Cancers (Basel). 2024; 16(13): 2399. doi:10.3390/cancers16132399
13. Liefaard MC, Moore KS, Mulder L, van den Broek D, Wesseling J, Sonke GS, et al. Tumour-educated platelets for breast cancer detection: biological and technical insights. Br J Cancer. 2023; 128(8): 1572-1581. doi:10.1038/s41416-023-02174-5
14. Mulder FI, Kraaijpoel N, Carrier M, Guman N, Jara-Palomares L, Di Nisio M, et al. Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study. J Thromb Haemost. 2023; 21(4): 905-916. doi: 10.1016/j.jtha.2023.01.003
15. D'Ambrosi S, Visser A, Antunes-Ferreira M, Poutsma A, Giannoukakos S, Sol N, et al. The Analysis of Platelet-Derived circRNA Repertoire as Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer. Cancers (Basel). 2021; 13(18): 4644. doi:10.3390/cancers13184644
16. D'Ambrosi S, Giannoukakos S, Antunes-Ferreira M, Pedraz-Valdunciel C, Bracht JWP, Potie N, et al. Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection. Int J Mol Sci. 2023; 24(5): 4881. doi:10.3390/ijms24054881
17. Saeed Hadi H, Abdulzahra Abbas S. Oxiditive Stress biomarkers levels in blood sample of Iraqi Breast cancer patients. Research Journal of Pharmacy and Technology. 2023; 16(5): 2364-8. doi: 10.52711/0974-360X.2023.00389
18. Sinha VB, Pandey N, Taneja P. Biomarker genes for gynaecological cancers. Res J Pharm Technol. 2016; 9(10): 1641-1646 Available from: http://dx.doi.org/10.5958/0974-360x.2016.00329.2
19. Rezkitha YAA, Mahmudah I, Supriyanto S, Danardono E, Waskito LA, I’tishom R, et al. The suitable biomarkers of colorectal cancer for developing countries. Res J Pharm Technol. 2025; 1899): 4527–35. Available from: http://dx.doi.org/10.52711/0974-360x.2025.00650
20. Khatri M, Dhar S, Ven P, Singh A. Understanding the pharmacological mechanisms of anticancer resistance: A multifaceted challenge in cancer treatment. Asian J Pharm Res. 2024; 14(2): 183–7. Available from: http://dx.doi.org/10.52711/2231-5691.2024.00030
21. Priya SS, Ramamurthy B. Lung cancer detection using image processing technique. Res J Pharm Technol. 2018; 11(5): 2045-49. Available from: http://dx.doi.org/10.5958/0974-360x.2018.00379.7
22. Rajarajeswari., Prassanna, Quadir Md A, Jackson J C, Sharma S, Rajesh. Skin Cancer Detection using Deep Learning. Res J Pharm Technol. 2022; 15(10): 4519–25. Available from: http://dx.doi.org/10.52711/0974-360x.2022.00758
23. Saravanan M, Kalpanapriya D. A Novel Iris Cancer Detection using wavelet and wavelet packet Transform. Res J Pharm Technol. 2018; 11(7): 2926-31. Available from: http://dx.doi.org/10.5958/0974-360x.2018.00540.1
24. Mujawar NK, Mulla JAS. Targeted drug delivery: Revolutionizing breast cancer treatment with lipid polymer hybrid nanoparticles. Res J Pharm Technol. 2025; 18(12): 6131-8. Available from: http://dx.doi.org/10.52711/0974-360x.2025.00886
25. Dawood AA, Jasim BI. The CRISPR Genome Editing Process is an Effective Advancement of Short-Term Cancer Treatment. Res. J. Pharma. Dosage Forms and Tech. 2021; 13(1): 54-56.doi: 10.5958/0975-4377.2021.00009.4
26. Kalyankar TM., Butle SR., Chamwad GN. Application of Nanotechnology in Cancer Treatment. Research J. Pharm. and Tech. 2012; 5(9): 1161-1167.
27. Armila Sen, Komal Kumar, Shaheen Khan, Priyanka Pathak, Arjun Singh. Current Therapy in Cancer: Advances, Challenges, and Future Directions. Asian Journal of Nursing Education and Research. 2024; 14(1): 77-4. doi: 10.52711/2349-2996.2024.00016